Terbinafine hydrochloride (HCl) + Griseofulvin
Phase 3Completed 0 watching 0 views this week📈 Rising
77
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Tinea Capitis
Conditions
Tinea Capitis
Trial Timeline
Jun 1, 2004 → —
NCT ID
NCT00117767About Terbinafine hydrochloride (HCl) + Griseofulvin
Terbinafine hydrochloride (HCl) + Griseofulvin is a phase 3 stage product being developed by Novartis for Tinea Capitis. The current trial status is completed. This product is registered under clinical trial identifier NCT00117767. Target conditions include Tinea Capitis.
Hype Score Breakdown
Clinical
27
Activity
18
Company
10
Novelty
9
Community
10
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT00117767 | Phase 3 | Completed |
Competing Products
20 competing products in Tinea Capitis